Valeo Pharma Inc. · OTC:VPHIF
Valeo Pharma — Investor Presentation (August 2023)
23 slides from Valeo Pharma's investor presentation, August 2023
Slide 1: Investor Presentation August 2023
Bringing Healthcare Innovation to Canadians Investor Presentation August 2023 TSX: VPH
Slide 2: Forward-Looking Statements
Forward-Looking Statements: This presentation, including the documents incorporated by reference herein, contains “forward-looking information” as defined under Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of historical fact contained in
Slide 3: Company Overview
Company Overview ➢ Fast-growing Canadian pharma company (Mtl H.O.) ➢ License/acquire Canadian rights to commercial prescription drugs ➢ 8X revenue growth (2020-2023) / Significant leverage built-in ➢ Pan-Canadian presence & coverage ➢ H.O. supported commercial infrastructure ➢ 130 employees (85 + Sa
Slide 4: Focus & Priorities
Focus & Priorities ➢ 3 Therapeutics Areas: - Respiratory / Severe Allergy - Ophthalmology - Hospital Specialty Products ➢ 6 High Growth Assets: - Asthma: Enerzair / Atectura - Allergy: Allerject - Ophtha: Xiidra / Simbrinza - Hospital: Redesca ➢ Canada: - 12K MDs / 250 Hospitals / 50K + visits / yea
Slide 5: 2021-2022: Transformative Product Additions
2021-2022: Transformative Product Additions Revenues ($M) 160 140 $135M 120 100 $100M 80 $60M 60 40 $27.7M 20 $13.6M $7.5M 0 FY 20 A FY 21 A FY 22 A FY 23 F FY 24 F FY 25 F Spec./Hosp. Ophthalmology Respiratory VALUE PROPOSITION: Significant Operating Leverage available with nominal additional costs
Slide 6: Diversified Portfolio: Significant Growth Potential Ahead
Diversified Portfolio: Significant Growth Potential Ahead ENERZAIR ATECTURA ALLERJECT XIIDRA SIMBRINZA REDESCA OTHERS 0 10 20 30 40 50 60 70 80 90 2023 Estimated Sales ($M) Peak Sales Potential ($M) TSX:VPH PAGE 6
Slide 7: Respiratory / Allergy Business Unit
Respiratory / Allergy Business Unit Est. 2023 Est. 2024 Est. Peak Sales RESPIRATORY / ALLERGY Revenues ($M) Revenues ($M) ($M) ENERZAIR® Asthma $90+ ATECTURA® Asthma $16M $40M $30+ ALLERJECT® Allergy $25+ $145 TSX:VPH PAGE 7
Slide 8: Asthma: Canadian Market Dynamics
Asthma: Canadian Market Dynamics ➢ 3.8 million Canadian asthma sufferers ➢ 1 million Suffer from moderate to severe ➢ 50% Suffer from poor symptoms control $800M* TRIPLE agents (Corticosteroids + DUAL agents (Corticosteroids + 2 Bronchodilators) ~$220M Bronchodilator) ~$330M Single Agent Dual Agents
Slide 9: Asthma: Enerzair / Atectura
ASTHMA: ENERZAIR / ATECTURA Launched in Q4-21 Triple Agent Therapy triple combination ICS/LABA/LAMA First in Class 350K Targeted patients population $80M + Peak sales 42% reduction in exacerbations vs Advair Fully reimbursed (Private & Public) Launched in Q4-21 Dual Agent Therapy Dual combination LA
Slide 10: Enerzair / Atectura: Prescription Trends (June 2023)
Enerzair / Atectura: Prescription Trends (June 2023) # of Prescribers # of Prescriptions 2,500 2,361 60,000 2,208 52,367 2,036 48,813 50,000 2,000 1,889 45,031 1,724 41,329 1,582 40,000 37,508 1,429 33,917 32,899 1,500 1,284 1,136 30,000 28,253 1,004 24,024 1,000 883 20,201 779 683 20,000 16,875 558
Slide 11: Allergy/Severe Reactions: Allerject
Allergy/Severe Reactions: ALLERJECT® Target market: 1M units / YR Market Size: $80M + / CAGR 5-8% Peak Sales: $25M / 30% market share Features Epipen (Market leader) Allerject Annual Revenues $75-80M $4-5M Pricing $95-105 Same Reimbursement 75% coverage Same Voice assisted No Yes FDA Guidance for De
Slide 12: Ophthalmology Business Unit
Ophthalmology Business Unit Est. 2023 Est. 2024 Est. Peak Sales Ophthalmology Revenues ($M) Revenues ($M) ($M) XIIDRA® Dry eye disease $25M $33M $30+ SIMBRINZA® Glaucoma $15+ $45 TSX:VPH PAGE 12
Slide 13: Ophthalmology Products
Ophthalmology Products Launched in Q4-22 Target market: 8M people, 2% treated with Rx, 1,200 ophthalmologists $80M market size Current market share: 24% Market CAGR: 5-6% Launched in Q4-22 Target market: 400,000 Canadians, 1,200 ophthalmologists $60M market size Current market share: 18% Market CAGR
Slide 14: Specialty Products Business Unit
Specialty Products Business Unit Est. 2023 Est. 2024 Est. Peak Sales Specialty Products Revenues ($M) Revenues ($M) ($M) REDESCA® Blood Thinner $22M $27M $25+ Pain, Parkinson, OTHERS® $15+ Oncology $40 TSX:VPH PAGE 14
Slide 15: Redesca (Biosimilar)
Redesca® (Biosimilar) LMWH Biosimilar Market insight: June-23 Monthly - IQVIA Launched in Q1-21 Target market: $180M $25M Peak sales 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Mar- May- Mar- May- Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Apr-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-2
Slide 16: Financials & Summary
Financials & Summary TSX: VPH
Slide 17: Sequential P&L Improvement
Sequential P&L Improvement Qtly Revenues, A.EBITDA (Loss) vs OPEX $15,000 9,000 8,000 $12,000 Q2-23 VS. Q2-22 7,000 $9,000 • 6th Qtr of revenue growth up 184% 6,000 • 6th Qtr of Adj. Gross Profit up 181% $6,000 5,000 • 6th Qtr of Adj. EBITDA loss reduction down 53% $3,000 4,000 3,000 2023 $0 Q3-21 Q
Slide 18: Sequential Gross Margin Improvement
Sequential Gross Margin Improvement TSX:VPH PAGE 18
Slide 19: Capital Structure
Capital Structure, (at August 3, 2023) CAPITALIZATION MILLIONS Shares Outstanding (Share Price - $0.345) 84.2 Options/RSUs (avg. price, $0.62) 7.9 Management & Insiders Warrants (avg. strike price $1.19) 15.6 aligned with Convertible debentures ($25.0M) 21.7 shareholders. Fully-Diluted Shares Outsta
Slide 20: Business Development: Pipeline & Opportunities
Business Development: Pipeline & Opportunities Timing of Market Valeo Business Unit Partner Product Stage Revenues Opportunities Global Big Pharma Marketed (5 Products) FY-23 $30M U.S. Spec. Pharma FDA Filed FY-25 $100M Ophthalmology U.S. Spec. Pharma H.C. Filing, US approved FY-24 / FY-25 $40M + U.
Slide 21: Leadership
Leadership Management Board of Directors Richard J. MacKay Maureen C. Brennan Founder, CEO, since 2003 Chairman Board Member Former Vice-Chairman 40+ years in private and of Stiefel Laboratories public health sector Former Director General Steve Saviuk Shriners Hospital Founder, CEO Michel Trudeau S
Slide 22: Investment Summary
Investment Summary ➢ Leading topline growth 2023, and beyond ➢ Commercial focus (no R&D / clinical trials) ➢ 6 growth assets launched/acquired last 2 yrs. ➢ Peak sales potential ≥ $230M ➢ Significant operating leverage already built-in ➢ Active BD&L efforts for additional products TSX:VPH PAGE 22
Slide 23: Contact Us
Contact Us PHONE 514-694-0150 EMAIL ir@valeopharma.com WEB www.valeopharma.com